Immunization
- Name
- Immunization
- Accession Number
- DBCAT001639
- Description
Deliberate stimulation of the host's immune response. ACTIVE IMMUNIZATION involves administration of ANTIGENS or IMMUNOLOGIC ADJUVANTS. PASSIVE IMMUNIZATION involves administration of IMMUNE SERA or LYMPHOCYTES or their extracts (e.g., transfer factor, immune RNA) or transplantation of immunocompetent cell producing tissue (thymus or bone marrow).
- Drugs
Drug Drug Description G17DT Immunogen Intended for the treatment of various forms of cancer. Axicabtagene ciloleucel A CAR T-cell therapy used to treat adults with large B-cell lymphomas and follicular lymphoma. Ebola Zaire vaccine (live, attenuated) A vaccine used in the prophylaxis of Ebola virus disease caused by the species of Zaire ebolaviruses. Brexucabtagene autoleucel A modified autologous chimeric antigen receptor (CAR) T cell therapy employing a modified murine anti-CD19 single-chain variable fragment linked to CD28 and CD3ΞΆ co-stimulatory domains for the treatment of patients with relapsed and refractory mantle cell lymphoma. - Drugs & Drug Targets
Drug Target Type Axicabtagene ciloleucel B-lymphocyte antigen CD19 target Brexucabtagene autoleucel B-lymphocyte antigen CD19 target